COMMUNIQUÉS West-GlobeNewswire

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
14/05/2026
Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004 trial in rapid oral [...]
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
14/05/2026
BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer [...]
CapsoVision Reports First Quarter 2026 Financial Results
14/05/2026
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported [...]
BioStem Technologies Reports First Quarter 2026 Financial Results
14/05/2026
POMPANO BEACH, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue [...]
Precipio Announces Q1 2026 Financial Results
14/05/2026
Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc [...]
NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
14/05/2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical [...]
AVITA Medical Reports First Quarter 2026 Financial Results
14/05/2026
VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company [...]
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
14/05/2026
TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based [...]
BioSyent Releases Financial Results for First Quarter 2026
15/05/2026
MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2026. Key highlights include: (CAD) Q1 [...]
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
14/05/2026
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Therapy Platform Enabled [...]
BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
14/05/2026
KUALA LUMPUR, MALAYSIA, May 14, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fire safety protection and [...]
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
14/05/2026
Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. Topline 12-month data from the BIM-IOL System [...]
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
14/05/2026
ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen [...]
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
First Tracks launched April 20 th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications SAN DIEGO, [...]
SRx Health Solutions Announces Fiscal Second Quarter 2026 Results for Quarter Ended March 31, 2026
14/05/2026
Q2 FY26 Marks Operational Inflection Point with Sequential 23% Revenue Growth and 44% Adjusted EBITDA Loss 1 Improvement Strengthened Liquidity and Working Capital Position with Cash of $20.5 million as of Quarter End [...]
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
14/05/2026
Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expertise in precision immunoengineering Enhanced the company’s portfolio with an exclusive license for, CUE-221, a Phase 2 [...]
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
14/05/2026
VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress’ [...]
BioSyent Declares Second Quarter 2026 Dividend
15/05/2026
MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common [...]

Pages